CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MED18 (ImmuneEditome ID:54797)

1. Gene summary of enriched editing regions for MED18

check button Gene summary
Gene informationGene symbol

MED18

Gene ID

54797

GeneSynonymsSRB5|p28b
GeneCytomap

1p35.3

GeneTypeprotein-coding
GeneDescriptionmediator of RNA polymerase II transcription subunit 18|TRAP/mediator complex subunit p28b|mediator of RNA polymerase II transcription, subunit 18 homolog
GeneModificationdate20230517
UniprotIDQ9BUE0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:28329513-28330145:+ENST00000475655.1ENSG00000130772.12MED18ncRNA_intronicAluJr4,AluSq2,MIR3,AluSpchr1:28329513-28330145:+.alignment
chr1:28329513-28330145:+ENST00000479574.4ENSG00000130772.12MED18ncRNA_intronicAluJr4,AluSq2,MIR3,AluSpchr1:28329513-28330145:+.alignment
chr1:28335018-28335861:+ENST00000398997.2ENSG00000130772.12MED18splicingAluSq2,AluSgchr1:28335018-28335861:+.alignment


Top

2. Tumor-specific enriched editing regions for MED18


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:28335018-28335861:+BRCAEER8.2511e-03image
ENSG00000130772.12,MED18BRCAEAG6.8881e-03image
chr1:28335018-28335861:+LIHCEER4.0977e-02image
ENSG00000130772.12,MED18LIHCEAG4.8859e-02image
chr1:28335018-28335861:+UCECEER1.3929e-02image
ENSG00000130772.12,MED18UCECEAG1.2992e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr1:28335018-28335861:+TGCTPathEER7.4125e-032.4651e-030.3300image
ENSG00000130772.12,MED18TGCTPathEAG1.1484e-023.8030e-030.3162image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for MED18


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:28335018-28335861:+COADEERENSG00000116731,PRDM20.21471.2427e-027.0739e-120.4021imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr1:28335018-28335861:+COADEERENSG00000230953,RP4-631H13.60.18264.0897e-021.0541e-130.4328imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28335018-28335861:+TGCTEERENSG00000196189,SEMA4A-0.44571.4250e-065.8717e-08-0.4175imageNELAVL1;FUS;IGF2BP2;PTBP1;U2AF2SEMA4AMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000107185,RGP10.45012.0849e-063.8197e-080.4228imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000150403,TMCO30.43364.9486e-066.6539e-100.4689imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr1:28335018-28335861:+TGCTEERENSG00000180398,MCFD20.42655.0236e-066.2276e-080.4168imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2MCFD2Macrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000113328,CCNG10.41465.8077e-061.4464e-100.4846imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2CCNG1Macrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000112419,PHACTR20.42091.0150e-051.2581e-070.4079imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000138069,RAB1A0.41301.3556e-055.4425e-080.4185imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+TGCTEERENSG00000107643,MAPK80.41821.8944e-051.4270e-070.4062imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2MAPK8Macrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for MED18


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000130772.12,MED18
COADEAGIRENSG00000122417.11chr186354773:86354859:86356443:863565440.20053.6682e-021.9956e-100.4200imageNADAR;AIFM1;CNBP;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;GNL3;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;QKI;RBM10;SAFB2;SND1;SRSF1;SRSF3;SRSF7;TARDBP;U2AF1;U2AF2;UPF1;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28335018-28335861:+
COADEERIRENSG00000122417.11chr186354773:86354859:86356443:863565440.20053.2447e-021.9956e-100.4200imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28335018-28335861:+
GBMEERIRENSG00000153187.12chr1244854972:244855036:244855423:244855608-0.15192.3096e-026.6035e-11-0.5010imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
ENSG00000130772.12,MED18
GBMEAGIRENSG00000153187.12chr1244854972:244855036:244855423:244855608-0.15212.6600e-026.4348e-11-0.5012imageNADAR;AIFM1;BUD13;CAPRIN1;CNBP;CPSF6;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;QKI;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
chr1:28335018-28335861:+
TGCTEERESENSG00000123349.9chr1253295581:53295639:53295838:53296275:53297849:532979240.40962.0733e-041.7840e-080.4320imageNELAVL1;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr1:28335018-28335861:+
TGCTEERMEXENSG00000197165.6chr1628592262:28592443:28593251:28593346:28595366:28595934:28596996:28597109-0.26445.2729e-031.1018e-06-0.4379imageNELAVL1;FUS;HNRNPC;IGF2BP2;U2AF2NAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:28335018-28335861:+
TGCTEERESENSG00000088367.16chr2036197879:36198041:36209487:36209898:36212271:362123760.26353.6271e-021.9087e-060.4008imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
ENSG00000130772.12,MED18
TGCTEAGIRENSG00000198755.6chr635468407:35468439:35468596:35468819-0.28191.2948e-025.2979e-08-0.4445imageNADAR;AIFM1;BUD13;CAPRIN1;CNBP;CPSF6;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;QKI;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
ENSG00000130772.12,MED18
TGCTEAGIRENSG00000089692.4chr126777263:6777921:6778243:67784530.30191.5541e-023.0798e-080.4413imageNADAR;BUD13;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;U2AF1;U2AF2LAG3Macrophages_M2GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr1:28335018-28335861:+
TGCTEERESENSG00000061938.12chr3195884974:195885033:195885412:195885543:195886976:195887047-0.41368.0778e-056.1632e-08-0.4219imageNELAVL1;FUS;HNRNPC;IGF2BP2;PTBP1;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for MED18


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:28335018-28335861:+ACCEERB_cells_memory1.6190e-030.3490image
ENSG00000130772.12,MED18ACCEAGB_cells_memory2.2147e-030.3394image
chr1:28335018-28335861:+BLCAEERMacrophages_M19.2562e-04-0.1644image
ENSG00000130772.12,MED18BLCAEAGMacrophages_M19.0775e-04-0.1646image
chr1:28335018-28335861:+BRCAEERT_cells_regulatory_(Tregs)2.0644e-06-0.1441image
ENSG00000130772.12,MED18BRCAEAGT_cells_regulatory_(Tregs)1.9771e-06-0.1443image
chr1:28335018-28335861:+CESCEERT_cells_CD4_memory_resting7.7061e-050.2248image
ENSG00000130772.12,MED18CESCEAGT_cells_CD4_memory_resting9.5358e-050.2219image
chr1:28335018-28335861:+CHOLEERMacrophages_M23.9654e-030.4746image
ENSG00000130772.12,MED18CHOLEAGMacrophages_M23.5893e-030.4792image
chr1:28335018-28335861:+COADEERT_cells_CD4_memory_resting1.0906e-020.1550image
ENSG00000130772.12,MED18COADEAGT_cells_CD4_memory_resting1.0906e-020.1550image
ENSG00000130772.12,MED18DLBCEAGT_cells_CD83.9325e-020.2985image
chr1:28335018-28335861:+ESCAEERMast_cells_resting4.1494e-030.2248image
ENSG00000130772.12,MED18ESCAEAGMast_cells_resting3.3886e-030.2296image
chr1:28335018-28335861:+HNSCEERMacrophages_M12.2952e-05-0.1887image
ENSG00000130772.12,MED18HNSCEAGMacrophages_M11.5694e-05-0.1924image
chr1:28335018-28335861:+KIRCEERNK_cells_activated1.6999e-03-0.1607image
ENSG00000130772.12,MED18KIRCEAGT_cells_CD81.8890e-03-0.1591image
ENSG00000130772.12,MED18KIRPEAGMast_cells_resting1.8964e-040.2190image
chr1:28335018-28335861:+LGGEERT_cells_CD4_naive1.5817e-020.1065image
ENSG00000130772.12,MED18LGGEAGT_cells_CD4_naive1.5449e-020.1069image
chr1:28335018-28335861:+LIHCEERMast_cells_resting3.3158e-02-0.1106image
ENSG00000130772.12,MED18LIHCEAGMast_cells_resting2.8498e-02-0.1137image
chr1:28335018-28335861:+LUADEERT_cells_CD4_memory_resting1.0941e-030.1448image
ENSG00000130772.12,MED18LUADEAGT_cells_regulatory_(Tregs)1.2564e-03-0.1430image
chr1:28335018-28335861:+LUSCEERMacrophages_M21.4998e-040.1698image
ENSG00000130772.12,MED18LUSCEAGMacrophages_M21.2556e-040.1717image
chr1:28335018-28335861:+MESOEERMast_cells_resting2.5036e-020.2474image
ENSG00000130772.12,MED18MESOEAGMast_cells_resting2.0266e-020.2560image
chr1:28335018-28335861:+OVEERT_cells_gamma_delta1.6316e-02-0.1405image
ENSG00000130772.12,MED18OVEAGT_cells_gamma_delta1.3267e-02-0.1448image
chr1:28335018-28335861:+PAADEEREosinophils3.8438e-030.2156image
ENSG00000130772.12,MED18PAADEAGEosinophils3.6125e-030.2170image
chr1:28335018-28335861:+PCPGEERMacrophages_M21.2632e-020.1871image
ENSG00000130772.12,MED18PCPGEAGMacrophages_M21.2632e-020.1871image
chr1:28335018-28335861:+PRADEERDendritic_cells_resting1.9600e-020.1048image
ENSG00000130772.12,MED18PRADEAGDendritic_cells_resting1.8570e-020.1057image
chr1:28335018-28335861:+READEERMast_cells_resting2.3171e-020.2328image
ENSG00000130772.12,MED18READEAGMast_cells_resting2.2571e-020.2338image
chr1:28335018-28335861:+SARCEERMast_cells_resting1.2205e-050.2696image
ENSG00000130772.12,MED18SARCEAGMast_cells_resting1.3437e-050.2684image
chr1:28335018-28335861:+SKCMEERT_cells_CD89.0233e-05-0.1798image
ENSG00000130772.12,MED18SKCMEAGT_cells_CD88.4255e-05-0.1805image
chr1:28335018-28335861:+STADEERMonocytes1.4952e-020.1306image
ENSG00000130772.12,MED18STADEAGMonocytes3.1981e-020.1152image
chr1:28335018-28335861:+TGCTEERMacrophages_M23.5531e-070.3942image
ENSG00000130772.12,MED18TGCTEAGMacrophages_M22.6130e-070.3983image
chr1:28335018-28335861:+THCAEEREosinophils1.8965e-030.1380image
ENSG00000130772.12,MED18THCAEAGEosinophils1.8484e-030.1384image
chr1:28335018-28335861:+THYMEERMacrophages_M14.3050e-05-0.3672image
ENSG00000130772.12,MED18THYMEAGMacrophages_M14.3050e-05-0.3672image
chr1:28335018-28335861:+UCECEERB_cells_naive1.4615e-020.1848image
ENSG00000130772.12,MED18UCECEAGB_cells_naive1.4092e-020.1858image
chr1:28335018-28335861:+UCSEERT_cells_follicular_helper4.9870e-02-0.2633image
ENSG00000130772.12,MED18UCSEAGT_cells_follicular_helper4.9870e-02-0.2633image


Top

6. Enriched editing regions and immune gene sets for MED18


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr1:28335018-28335861:+STADEER1.8833e-02image2.9798e-040.1930image
ENSG00000130772.12,MED18STADEAG2.6246e-02image5.2499e-040.1852image
chr1:28335018-28335861:+THCAEER2.1203e-02image1.0228e-05-0.1951image
ENSG00000130772.12,MED18THCAEAG2.1802e-02image1.0116e-05-0.1952image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:28335018-28335861:+LIHCEER4.7806e-020.10282.3852e-020.11733.7689e-020.10794.8223e-030.1461image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:28335018-28335861:+ACCGSVA_HALLMARK_KRAS_SIGNALING_UPEER6.7464e-03-0.3024image
ENSG00000130772.12,MED18ACCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG7.0790e-03-0.3007image
ENSG00000130772.12,MED18BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.2809e-08-0.2709image
chr1:28335018-28335861:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.8430e-08-0.2721image
chr1:28335018-28335861:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4389e-16-0.2481image
ENSG00000130772.12,MED18BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.4222e-17-0.2509image
chr1:28335018-28335861:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0659e-08-0.3207image
ENSG00000130772.12,MED18CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2125e-08-0.3195image
ENSG00000130772.12,MED18COADGSVA_HALLMARK_UV_RESPONSE_UPEAG3.4339e-04-0.2167image
chr1:28335018-28335861:+COADGSVA_HALLMARK_UV_RESPONSE_UPEER3.4339e-04-0.2167image
ENSG00000130772.12,MED18ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.4135e-020.1931image
chr1:28335018-28335861:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.6698e-020.1884image
ENSG00000130772.12,MED18GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.3752e-04-0.2765image
chr1:28335018-28335861:+GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.3673e-04-0.2766image
ENSG00000130772.12,MED18HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6213e-10-0.2817image
chr1:28335018-28335861:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2396e-10-0.2796image
ENSG00000130772.12,MED18KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.9784e-030.1476image
chr1:28335018-28335861:+KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEER3.8342e-030.1482image
ENSG00000130772.12,MED18KIRPGSVA_HALLMARK_UV_RESPONSE_UPEAG1.4846e-02-0.1439image
ENSG00000130772.12,MED18LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.1855e-02-0.3040image
chr1:28335018-28335861:+LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER7.0281e-030.1189image
ENSG00000130772.12,MED18LGGGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.3641e-030.1182image
ENSG00000130772.12,MED18LIHCGSVA_HALLMARK_HYPOXIAEAG6.4450e-030.1412image
chr1:28335018-28335861:+LIHCGSVA_HALLMARK_HYPOXIAEER4.8223e-030.1461image
chr1:28335018-28335861:+LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER5.9567e-040.1521image
ENSG00000130772.12,MED18LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG6.4149e-040.1512image
ENSG00000130772.12,MED18LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5691e-05-0.1881image
chr1:28335018-28335861:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7505e-05-0.1875image
ENSG00000130772.12,MED18OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.4729e-020.1426image
chr1:28335018-28335861:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.0169e-020.1359image
ENSG00000130772.12,MED18PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8184e-06-0.3428image
chr1:28335018-28335861:+PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6677e-06-0.3436image
ENSG00000130772.12,MED18PCPGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.1826e-02-0.1532image
chr1:28335018-28335861:+PCPGGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.1826e-02-0.1532image
chr1:28335018-28335861:+PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.3470e-040.1645image
ENSG00000130772.12,MED18PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.3322e-040.1645image
chr1:28335018-28335861:+READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.9282e-020.2119image
ENSG00000130772.12,MED18READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.6169e-020.2153image
chr1:28335018-28335861:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1793e-07-0.3237image
ENSG00000130772.12,MED18SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1228e-07-0.3242image
ENSG00000130772.12,MED18SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0079e-07-0.2296image
chr1:28335018-28335861:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.4124e-07-0.2289image
ENSG00000130772.12,MED18STADGSVA_HALLMARK_MYOGENESISEAG2.2468e-040.1968image
chr1:28335018-28335861:+STADGSVA_HALLMARK_MYOGENESISEER1.0821e-040.2063image
chr1:28335018-28335861:+TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.5708e-080.4336image
ENSG00000130772.12,MED18TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.5300e-080.4339image
chr1:28335018-28335861:+THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.6504e-09-0.2612image
ENSG00000130772.12,MED18THCAGSVA_HALLMARK_COMPLEMENTEAG2.6682e-09-0.2611image
chr1:28335018-28335861:+THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.4761e-07-0.4487image
ENSG00000130772.12,MED18THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.4761e-07-0.4487image
ENSG00000130772.12,MED18UCECGSVA_HALLMARK_UV_RESPONSE_UPEAG1.8943e-04-0.2793image
chr1:28335018-28335861:+UCECGSVA_HALLMARK_UV_RESPONSE_UPEER2.0642e-04-0.2778image
ENSG00000130772.12,MED18UCSGSVA_HALLMARK_MYC_TARGETS_V2EAG1.4805e-020.3241image
chr1:28335018-28335861:+UCSGSVA_HALLMARK_MYC_TARGETS_V2EER1.4805e-020.3241image


Top

7. Enriched editing regions and drugs for MED18


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000130772.12,MED18BLCACGP.60474EAG4.3746e-050.2021image
chr1:28335018-28335861:+BLCACGP.60474EER3.3578e-050.2050image
ENSG00000130772.12,MED18BRCAGW843682XEAG5.8298e-110.1978image
chr1:28335018-28335861:+BRCAGW843682XEER9.1651e-110.1958image
ENSG00000130772.12,MED18CESCAZD6244EAG1.0343e-050.2499image
chr1:28335018-28335861:+CESCAZD6244EER1.0045e-050.2503image
ENSG00000130772.12,MED18COADBMS.509744EAG4.0538e-050.2475image
chr1:28335018-28335861:+COADBMS.509744EER4.0538e-050.2475image
ENSG00000130772.12,MED18DLBCAZD.2281EAG2.8390e-020.3165image
ENSG00000130772.12,MED18ESCAGNF.2EAG2.3062e-03-0.2386image
chr1:28335018-28335861:+ESCAImatinibEER3.4786e-03-0.2290image
ENSG00000130772.12,MED18GBMBMS.536924EAG2.4877e-030.2347image
chr1:28335018-28335861:+GBMBMS.536924EER2.3753e-030.2357image
chr1:28335018-28335861:+HNSCBexaroteneEER5.3932e-050.1801image
ENSG00000130772.12,MED18HNSCBexaroteneEAG5.6330e-050.1796image
ENSG00000130772.12,MED18KIRCGDC.0449EAG8.2865e-070.2503image
chr1:28335018-28335861:+KIRCGDC.0449EER8.4080e-070.2501image
ENSG00000130772.12,MED18KIRPLapatinibEAG2.8854e-04-0.2128image
ENSG00000130772.12,MED18LAMLFTI.277EAG1.9114e-03-0.4284image
chr1:28335018-28335861:+LGGKU.55933EER1.3733e-030.1411image
ENSG00000130772.12,MED18LGGKU.55933EAG1.2778e-030.1420image
ENSG00000130772.12,MED18LIHCDasatinibEAG4.8557e-030.1573image
chr1:28335018-28335861:+LIHCDasatinibEER4.2591e-030.1596image
chr1:28335018-28335861:+LUADErlotinibEER2.2277e-040.1634image
ENSG00000130772.12,MED18LUADErlotinibEAG2.2315e-040.1634image
chr1:28335018-28335861:+LUSCCamptothecinEER2.2714e-030.1370image
ENSG00000130772.12,MED18LUSCCamptothecinEAG2.1930e-030.1375image
ENSG00000130772.12,MED18MESOAMG.706EAG2.6738e-02-0.2447image
chr1:28335018-28335861:+MESOAMG.706EER2.6282e-02-0.2454image
chr1:28335018-28335861:+OVImatinibEER1.0333e-02-0.1499image
ENSG00000130772.12,MED18OVImatinibEAG8.1804e-03-0.1545image
ENSG00000130772.12,MED18PAADGefitinibEAG7.2723e-030.2011image
chr1:28335018-28335861:+PAADGefitinibEER8.7537e-030.1965image
chr1:28335018-28335861:+PCPGAKT.inhibitor.VIIIEER1.9069e-03-0.2318image
ENSG00000130772.12,MED18PCPGAKT.inhibitor.VIIIEAG1.9069e-03-0.2318image
ENSG00000130772.12,MED18PRADGNF.2EAG3.9526e-040.1588image
chr1:28335018-28335861:+PRADGNF.2EER3.6639e-040.1597image
ENSG00000130772.12,MED18READBosutinibEAG3.4703e-020.2170image
chr1:28335018-28335861:+READBosutinibEER3.4627e-020.2170image
ENSG00000130772.12,MED18SARCAP.24534EAG9.0900e-050.2421image
chr1:28335018-28335861:+SARCAP.24534EER9.7847e-050.2411image
ENSG00000130772.12,MED18SKCMCI.1040EAG7.1265e-050.1824image
chr1:28335018-28335861:+SKCMCI.1040EER6.9617e-050.1826image
ENSG00000130772.12,MED18STADBIBW2992EAG3.7026e-040.1917image
chr1:28335018-28335861:+STADBIBW2992EER2.7623e-040.1958image
chr1:28335018-28335861:+TGCTBMS.754807EER3.7825e-06-0.3605image
ENSG00000130772.12,MED18TGCTBMS.754807EAG3.1121e-06-0.3634image
chr1:28335018-28335861:+THCACI.1040EER2.4255e-060.2082image
ENSG00000130772.12,MED18THCACI.1040EAG2.4174e-060.2082image
ENSG00000130772.12,MED18THYMDoxorubicinEAG5.3520e-07-0.4422image
chr1:28335018-28335861:+THYMDoxorubicinEER5.3520e-07-0.4422image
ENSG00000130772.12,MED18UCECCGP.60474EAG1.3696e-030.2408image
chr1:28335018-28335861:+UCECCGP.60474EER1.9154e-030.2337image
ENSG00000130772.12,MED18UVMCI.1040EAG3.5966e-020.2364image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType